SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 Study for Pancreatic Cancer First dose at HOAG Health in FAPI-PRO trial for Pancreatic Ductal Adenocarcinoma A …

Feb 11, 2026 · With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high-value theranostic intellectual property, SOFIE is poised to …

SOFIE has built a high-capacity PET radiopharmaceutical network capable of delivering large volumes of products to as many patients as possible. Our product lines include FDG, Pylarify, Neuraceq, and …

In 2006, the creation of SOFIE launched the aspiration of having a multifaceted approach to expand the reach of PET products for patients with advanced imaging needs. This was further realized in 2017 …

Jan 27, 2026 · Seven SOFIE radiopharmacies now produce the FAP-targeting radiopharmaceutical, as SOFIE launches Phase 3 clinical trials and support of Pharma and Academic groups.

Our team works alongside our Pharma and Academic partners to revolutionize clinical diagnostics and therapeutics to better understand and treat the biology of disease.

Jan 23, 2026 · Results from SOFIE’s Phase 2 diagnostic study on [18F]FAPI-74 PET were presented to the oncological community at the esteemed ASCO Gastrointestinal (GI) Cancers Symposium held in …

Apr 1, 2025 · With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value Theranostic intellectual property, SOFIE is poised to …

Nov 17, 2025 · Another defining moment for SOFIE Biosciences! Last Friday, November 14, 2025, FAPI-GO, SOFIE’s FAPI-74 Phase 3 study in gastroesophageal cancers, officially went live! The first …

Transparency in Coverage (TiC) regulations requires health insurers and group Health Plans to post their provider link on company websites. View SOFIE’s Link here View our Privacy Policy